Corbus Pharmaceuticals Holdings (CRBP) Given News Sentiment Score of 0.12

Media headlines about Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Corbus Pharmaceuticals Holdings earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 47.0697624785785 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment’s scoring:

Corbus Pharmaceuticals Holdings (CRBP) opened at 7.15 on Tuesday. The company’s 50 day moving average is $7.00 and its 200 day moving average is $6.57. Corbus Pharmaceuticals Holdings has a 1-year low of $4.75 and a 1-year high of $10.50. The company’s market cap is $359.07 million.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.04. The firm had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $0.50 million. Corbus Pharmaceuticals Holdings had a negative net margin of 1,001.77% and a negative return on equity of 107.10%. Equities research analysts forecast that Corbus Pharmaceuticals Holdings will post ($0.64) EPS for the current year.

Several equities research analysts have recently commented on the stock. Noble Financial restated a “buy” rating and issued a $16.00 price target on shares of Corbus Pharmaceuticals Holdings in a report on Friday, September 29th. Cantor Fitzgerald restated a “buy” rating and issued a $24.00 price target on shares of Corbus Pharmaceuticals Holdings in a report on Wednesday, September 20th. ValuEngine lowered shares of Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a report on Wednesday, September 13th. Finally, BidaskClub upgraded shares of Corbus Pharmaceuticals Holdings from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $19.75.

TRADEMARK VIOLATION NOTICE: This article was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at

Corbus Pharmaceuticals Holdings Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

What are top analysts saying about Corbus Pharmaceuticals Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corbus Pharmaceuticals Holdings Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit